Relay Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Revenue	10.01	25.55	1.38	3.03	82.65	Upgrade
Revenue Growth (YoY)	-60.83%	1749.82%	-54.41%	-96.34%	-	Upgrade
Cost of Revenue	315.44	326.39	243.01	169.39	96.59	Upgrade
Gross Profit	-305.43	-300.84	-241.62	-166.36	-13.94	Upgrade
Selling, General & Admin	80.24	78.58	69.33	59.75	41.86	Upgrade
Operating Expenses	80.24	78.58	69.33	59.75	41.86	Upgrade
Operating Income	-385.67	-379.42	-310.95	-226.11	-55.8	Upgrade
Interest & Investment Income	34.75	31.05	8.79	0.83	3.4	Upgrade
Other Non Operating Income (Expenses)	0.01	-0.02	-0.02	-0	-0.02	Upgrade
EBT Excluding Unusual Items	-350.91	-348.4	-302.19	-225.28	-52.41	Upgrade
Merger & Restructuring Charges	-	-	-	-0.9	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-11.86	-	Upgrade
Other Unusual Items	13.21	6.42	11.68	-2.84	-	Upgrade
Pretax Income	-337.71	-341.97	-290.51	-363.87	-52.41	Upgrade
Net Income	-337.71	-341.97	-290.51	-363.87	-52.41	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	177.79	Upgrade
Net Income to Common	-337.71	-341.97	-290.51	-363.87	-230.2	Upgrade
Shares Outstanding (Basic)	143	123	112	95	43	Upgrade
Shares Outstanding (Diluted)	143	123	112	95	43	Upgrade
Shares Change (YoY)	16.55%	9.21%	17.97%	123.22%	1135.17%	Upgrade
EPS (Basic)	-2.36	-2.79	-2.59	-3.82	-5.40	Upgrade
EPS (Diluted)	-2.36	-2.79	-2.59	-3.82	-5.40	Upgrade
Free Cash Flow	-251.13	-304.44	-238.55	-77.88	-104.42	Upgrade
Free Cash Flow Per Share	-1.76	-2.48	-2.13	-0.82	-2.45	Upgrade
Gross Margin	-	-	-	-	-16.86%	Upgrade
Operating Margin	-3854.04%	-1485.25%	-22516.44%	-7464.74%	-67.51%	Upgrade
Profit Margin	-3374.72%	-1338.66%	-21036.13%	-12012.94%	-278.51%	Upgrade
Free Cash Flow Margin	-2509.49%	-1191.74%	-17273.86%	-2571.05%	-126.33%	Upgrade
EBITDA	-380.21	-374.15	-306.82	-222.18	-52.25	Upgrade
EBITDA Margin	-	-	-	-	-63.21%	Upgrade
D&A For EBITDA	5.46	5.27	4.13	3.93	3.55	Upgrade
EBIT	-385.67	-379.42	-310.95	-226.11	-55.8	Upgrade
EBIT Margin	-	-	-	-	-67.51%	Upgrade
Revenue as Reported	10.01	25.55	1.38	3.03	82.65	Upgrade

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q